For both Life shareholders, who wanted out, and Thermo, who can probably make the numbers work, this looks like a good deal, with limited downside and lots of potential upside if Torren does become a player in medicine, not just benchtop science.
FORBES: What Does This $14 Billion Deal Mean For The Future Of DNA Sequencing?